The UK could find its ability to counter the threat of a ‘super-gonorrhoea’ and other infectious diseases hampered if the country loses access to the EU’s early warning health system, the B
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.